The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback